Did you know?

Compare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...One reason why now's a decent time to buy psychedelics stocks is that there's an ongoing fire sale across the entire industry, thanks to the bear market. Leaders like COMPASS Pathways ( CMPS 3.22% ...*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. COMPASS Pathways Analyst Opinions. All. All ...Compass shares are also dragging in late 2023, down 26.3% on a year-to-date basis. The U.K.-based biotech, which specializes in psilocybin research for treating depression, recently landed $285 ...CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...(Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...WebA live webcast of the call will be available on COMPASS Pathway’s website at: First Quarter 2023 Financial Results. The webcast will also be available on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days. The call will also be webcast on the COMPASS Pathways website and archived for 30 days.WebUK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.Compare with up to 5 Stocks. On Monday 11/06/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.05 on NAS. Compared to the opening price on Monday 11/06/2023 on NAS of ...WebStock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.TipRanksCOMPASS Pathways PLC ADR analyst ratings, historical stock price The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. Compass Pathways Plc. Market Cap. $399M. The COMPASS Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on August [3], 2023. Please register in advance here to access the call and obtain a local or toll-free phone number and personal pin. A live webcast of the call will be available on COMPASS Pathway’s website at: Second Quarter 2023 Financial …Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...Web Compass Pathways (CMPS) buy sell technical analysis &am

06:48 PM ET 11/23/2020. Atai Life Sciences, a company that backs Compass Pathways ( CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the ...Research COMPASS Pathways' (Nasdaq:CMPS) stock key valuation metrics while comparing it with its industry peers & market side by side. Research COMPASS ... The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual …May 6, 2023 · On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) has given the green light for three new current procedural terminology (CPT) codes for psychedelic ... Overall, the consensus among analysts is that Compass Pathways has a promising future ahead. CMPS Stock Analysis: Fluctuating Prices and Negative Earnings Growth, but Positive Forecast for the Future. On May 11, 2023, CMPS stock opened at the same price as the previous close, which was 8.59. Throughout the day, the stock’s price fluctuated ...Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.

Jul 1, 2023 · While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months. According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 668.99%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. A company's cash runway is the amount of time i. Possible cause: COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Le.